Dexamethasone News and Research

RSS

DSMB recommends discontinuation of Aeterna Zentaris’ perifosine Phase 3 study for MM

Aeterna Zentaris Inc. today announced that an independent Data Safety Monitoring Board has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.

12 Mar 2013

Early detection, treatment needed to reduce risk of death and CVD in older Cushing's disease patients

Even after successful treatment, patients with Cushing's disease who were older when diagnosed or had prolonged exposure to excess cortisol face a greater risk of dying or developing cardiovascular disease, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

13 Feb 2013

Intratympanic versus systemic steroid improves sudden hearing loss

Intratympanic treatment with the steroid dexamethasone should be considered as a salvage therapy for patients who have not responded to systemic treatment for sudden sensorineural hearing loss, suggest study findings.

12 Feb 2013

Celgene's Pomalyst receives FDA approval for treatment of multiple myeloma

The U.S. Food and Drug Administration today approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.

10 Feb 2013

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

10 Feb 2013

Botox relieves plantar fasciitis pain

Botulinum toxin A may be more effective than steroids for the treatment of plantar fasciitis, research suggests.

25 Jan 2013

Pomalidomide safe, effective and extends overall survival for patients with multiple myeloma

Researchers at Moffitt Cancer Center and colleagues have investigated the safety, efficacy and the maximum tolerated dose of pomalidomide for patients with multiple myeloma who have disease relapsed after treatments with other drugs, such as bortezomib and lenalidomide.

24 Jan 2013

Pomalidomide safe and effective in treating multiple myeloma

A new oral agent under review by the U.S. Food and Drug Administration (FDA) is safe and effective in treating relapsed and treatment-resistant multiple myeloma, according to a multicenter, Phase II study presented by Mount Sinai School of Medicine researchers at the American Society of Hematology (ASH) Annual Meeting. The meeting is taking place December 8-11, 2012 in Atlanta.

11 Dec 2012

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the presentation of new clinical data with the Company's targeted anticancer compound, IMGN901.

11 Dec 2012

New study could help develop anti-inflammatory drugs with fewer side effects

10 Dec 2012

Nanoparticle-based drug delivery attacks cancer cells without harming normal ones

This month, Molecular Pharmaceutics reported promising findings from the Nemours Center for Childhood Cancer Research and the Materials Science and Engineering Department at the University of Delaware, about the potential for nanotechnology to deliver chemotherapeutic agents in a way that attacks cancer cells without harming healthy cells.

5 Dec 2012

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012

Acetylon's ective histone deacetylase inhibitors to be showcased at 54th ASH annual meeting

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced that its selective histone deacetylase (HDAC) inhibitors will be featured in five posters and one oral presentation at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place December 8-11, 2012, in Atlanta, Georgia.

21 Nov 2012

Array BioPharma first quarter 2013 revenue decreases to $15.8 million

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2013.

30 Oct 2012

Anesthetic-loaded liposomes can delay onset of neuropathic pain

Using tiny spheres filled with an anesthetic derived from a shellfish toxin, researchers at Boston Children's Hospital and the Massachusetts Institute of Technology have developed a way to delay the rise of neuropathic pain, a chronic form of pain that arises from flawed signals transmitted by damaged nerves.

10 Oct 2012

Chinese medicine boosts hearing recovery after sudden deafness

Intravenous administration of a natural antioxidant used in Chinese medicine significantly improves the recovery of hearing after sudden deafness compared with standard therapy, the results of a Chinese study indicate.

2 Oct 2012

Steroid use during tonsillectomy does not raise excessive bleeding risk

Children who are given dexamethasone during tonsillectomy are not more likely to experience excessive bleeding after surgery than those who do not receive the steroid perioperatively, study findings suggest.

2 Oct 2012

NOXXON commences NOX-A12 Phase IIa trial in relapsed MM

NOXXON Pharma today announced the treatment of the first cohort of three multiple myeloma (MM) patients in a Phase IIa clinical trial of its anti-CXCL12/SDF-1 (CXC chemokine ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer NOX-A12.

26 Sep 2012

Dexamethasone use during tonsillectomy not associated with excessive bleeding in children

Tonsillectomy is exceedingly common, with a reported increase in tonsillectomy rates in children younger than 15 years from 287,000 to 530,000 per year over the past decade. Although safe, adenotonsillectomy can result in significant complications, such as aspiration and bleeding. Complications are infrequent, but because tonsillectomy is so common, the absolute number of children experiencing tonsillectomy complications is formidable.